Shanghai Pharmaceutical 4 billion to buy Citic Medicine today's volume rose 7.9%

NetEase Finance November 30 News this month, China Resources North Medicine has just passed its northern medicine shares injected 1 billion yuan holdings Xuzhou Li ' an Pharmaceutical Co., Ltd., approaching the base of the new medicine, now, Shanghai Pharmaceutical (601607.　　SH) is about to retaliate against a larger takeover of the China Resources North Medicine base in Beijing. Shanghai Medicine announced yesterday that it would acquire CHS controlling power, thereby substantially controlling Citic Pharmaceutical Industrial Co., Ltd. (hereinafter referred to as "Citic Medicine") to further expand the resources of the pharmaceutical distribution network in North China. According to other people close to the transaction, the transaction amount should not exceed 4 billion yuan.　　But the price will become the largest merger and acquisition deal since the Shanghai pharmaceutical reorganization, and is the largest drug acquisition case in the country.　　According to the Shanghai Medical Bulletin, the transaction lockout period is 2 months, but according to insiders speculate, within 1 months is expected to sign a formal agreement. CHS is a limited liability company registered in Caimas, Is., holding 100% of private equity funds and its substantive assets are CITIC Medicine. Citic Pharmaceuticals ranked 18th in China's pharmaceutical commercial enterprises in 2009, with the main business concentrated in the Beijing market and the third place in the market share.　　Citic Medicine in 2009 to achieve a net sales revenue of 4.3 billion yuan, 2010 this figure is expected to exceed 6 billion yuan.　　Shanghai Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Caimas, Is., Shanghai Industrial Medicine Technology (Group) Limited (hereinafter referred to as "the real medicine") as an acquisition entity, acquired Northernlightventurecapitalii,ltd and held a 2.6% per cent stake in CHS Total equity. On the same day, Shanghai pharmaceutical and medical practitioners and CHS shareholders of the China Fund, Lai Lai Asia Venture Fund and NEA Fund to achieve an irrevocable exclusive purchase letter of intent to acquire the chs55.45% Equity holdings of the Fund.　　Shanghai Medicine thus fully holding CHS. After the completion of this acquisition, Shanghai Medicine will realize the historic strategic breakthrough in North China, especially in Beijing market.　　Beijing has long been the most important health resource gathering center in China and the largest medical center in North China, which bears the needs of high-end medical service in the whole country, especially in North China, Midwest and Northeast.　　News stimulation, Shanghai Medicine today a sharp 7.1%, soon after the impact of trading, due to the market turmoil, the close of the Shanghai Medical newspaper received 25.7 yuan, or 7.94%, a transaction of 1.111 billion yuan, turnover sharply enlarged. Related news: Shanghai pharmaceutical or 4 billion acquisition of CITIC Medicine development Distribution network